What is CHS
This fact-check may be outdated. Consider refreshing it to get the most current information.
Executive summary
Cannabinoid hyperemesis syndrome (CHS) is a paradoxical condition in which chronic, frequent cannabis use leads to cyclical episodes of severe nausea, abdominal pain and prolonged vomiting that are often relieved temporarily by hot showers; stopping cannabis is the only known cure [1] [2]. The syndrome is increasingly recognized in emergency departments as legalization and chronic use rise, but its precise biological mechanism, true incidence, and overlap with similar disorders remain contested [3] [4].
1. What CHS is — a clinical definition and paradox
CHS is defined as recurrent episodes of severe vomiting and nausea that occur in people who have used cannabis regularly for months to years, a counterintuitive outcome given cannabis’s established antiemetic properties [1] [5]. First described in the medical literature in 2004, CHS is characterized by symptom-free intervals punctuated by acute, sometimes prolonged, vomiting episodes that can lead to dehydration and emergency care [2] [3].
2. Symptoms, distinctive behaviors and patient experience
Patients with CHS commonly report intense nausea, abdominal cramping, repeated vomiting, weight loss and a striking compulsion for long, hot showers or baths that temporarily relieve symptoms — the “hot shower” phenomenon has become a diagnostic clue because many sufferers report temperature-dependent relief [1] [2]. Clinicians note that sufferers often present in emergency departments in acute distress and may describe cycles of months or years between major bouts, making the pattern hard to spot unless cannabis use is specifically explored [6] [7].
3. Who is at risk and what the data show
CHS appears predominantly in people who use cannabis frequently — typically weekly to daily use over many years — and while originally thought to require a decade of use, reports suggest variable timelines and that not all heavy users develop the syndrome [3] [8]. Observational studies and emergency-department data point to rising CHS-related visits in jurisdictions with legalized retail cannabis, with some studies documenting substantial relative increases in ER presentations tied to cannabis-related vomiting [3] [6].
4. Diagnosis, differential diagnosis and management
There is no single diagnostic test for CHS; diagnosis relies on clinical history of chronic cannabis exposure plus the characteristic vomiting pattern and response to cessation, and clinicians must exclude infectious, gastrointestinal and neurologic causes as well as cyclic vomiting syndrome (CVS), which can mimic CHS but does not resolve with stopping cannabis [2] [4]. Acute management is supportive — hydration, antiemetics and symptom control in the ER — but the only definitive treatment documented is complete abstinence from cannabis, after which symptoms typically remit within weeks though some patients report longer recovery [1] [2].
5. Mechanistic uncertainty, controversies and public-health implications
The biological mechanism remains unclear and debated: hypotheses include cannabinoid receptor dysregulation, altered gut motility, and interactions with the endocannabinoid system, but none are proven, which complicates prevention and targeted therapy development [2]. Debate also surrounds incidence estimates and terminology — some clinicians argue CHS is underrecognized and rising with broader cannabis availability, while others note diagnostic overlap with CVS and potential reporting biases as patients and clinicians become more aware [3] [4].
6. Ambiguities in the acronym and reporting cautions
The letters “CHS” can denote other entities — for example, dictionary entries show CHS used as an acronym for unrelated phrases and media reports use CHS to refer to “confidential human source” in law‑enforcement contexts, and even a corporate name (CHS Inc.) exists — underscoring the need to use context when interpreting the acronym [9] [10]. Reporting on CHS in medicine benefits from precise language: conflating public-health trends, legal debates about cannabis, or unrelated acronyms risks confusion and miscommunication about the clinical syndrome documented in multiple medical and public-health sources [3] [2].